ArticleJournal of neurotrauma2014
The cancer drug tamoxifen: a potential therapeutic treatment for spinal cord injury.
Article in Journal of neurotrauma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Tibolone Improves Motor Recovery and Regulates Neuroinflammation and Gliosis in a Model of Traumatic Spinal Cord Injury.International journal of molecular sciences · 2025Article
- Tibolone Improves Locomotor Function in a Rat Model of Spinal Cord Injury by Modulating Apoptosis and Autophagy.International journal of molecular sciences · 2023Article
- Administration of Tamoxifen Can Regulate Changes in Gene Expression during the Acute Phase of Traumatic Spinal Cord Injury.Current issues in molecular biology · 2023Article
- The Role of Aquaporins in Spinal Cord Injury.Cells · 2023Review
- Targeting Estrogen Signaling in the Radiation-induced Neurodegeneration: A Possible Role of Phytoestrogens.Current neuropharmacology · 2023Review
- Double-edged effects of tamoxifen-in-oil-gavage on an infectious murine model for multiple sclerosis.Brain pathology (Zurich, Switzerland) · 2021Article
- Tamoxifen Application Is Associated with Transiently Increased Loss of Hippocampal Neurons following Virus Infection.International journal of molecular sciences · 2021Article
- Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets.Molecular neurobiology · 2020Review
- Delayed short-term tamoxifen treatment does not promote remyelination or neuron sparing after spinal cord injury.PloS one · 2020Article
- Matrine promotes neural circuit remodeling to regulate motor function in a mouse model of chronic spinal cord injury.Neural regeneration research · 2019Article
- Oligodendroglia Are Particularly Vulnerable to Oxidative Damage after NeurotraumaThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- Continuous tamoxifen delivery improves locomotor recovery 6h after spinal cord injury by neuronal and glial mechanisms in male rats.Experimental neurology · 2018Article
- Hormonal therapy in traumatic spinal cord injury.American journal of translational research · 2017Review
- Aquaporins in the Spinal Cord.International journal of molecular sciences · 2016Review
- Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats.Journal of neurotrauma · 2016Article
- Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery.Neural regeneration research · 2016Review
- Inhibition of Autophagy by Estradiol Promotes Locomotor Recovery after Spinal Cord Injury in Rats.Neuroscience bulletin · 2016Article
- Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats.Journal of veterinary medicine · 2016Article
- XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Challenges and Potential for Ovarian Preservation with SERMs.Biology of reproduction · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tamoxifen (TMX) is a selective estrogen receptor modulator that can mimic the neuroprotective effects of estrogen but lacks its systemic adverse effects. We found that TMX (1 mg/day) significantly improved the motor recovery of partially paralyzed hind limbs of male adult rats with thoracic spinal cord injury (SCI), thus indicating a translational potential for this cancer medication given its clinical safety and applicability and the lack of currently available treatments for SCI. To shed light on the mechanisms underlying the beneficial effects of TMX for SCI, we used proteomic analyses, Western blots and histological assays, which showed that TMX treatment spared mature oligodendrocytes/increased myelin levels and altered reactive astrocytes, including the upregulation of the water channels aquaporin 4 (AQP4), a novel finding. AQP4 increases in TMX-treated SCI rats were associated with smaller fluid-filled cavities with borders consisting of densely packed AQP4-expressing astrocytes that closely resemble the organization of normal glia limitans externa (in contrast to large cavities in control SCI rats that lacked glia limitans-like borders and contained reactive glial cells). Based on our findings, we propose that TMX is a promising candidate for the therapeutic treatment of SCI and a possible intervention for other neuropathological conditions associated with demyelination and AQP4 dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.